Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Cautious Optimism for IT Spending in 2026

    As IT budgets stabilize, AI-led modernization is unlocking new opportunities for service providers and investors in 2026.

    Read more

  • Replay: Macro Perspectives from William Blair’s 46th Annual Growth Stock Conference

    During the 46th annual Growth Stock Conference, William Blair macro analyst Richard de Chazal examined a changing macro backdrop, highlighting a shift toward a more structurally inflationary environment.

    Watch the video

  • Fervo Energy Company: Initiation of Research Coverage

    William Blair initiated research coverage of Fervo Energy Company (FRVO $37.22), a developer, owner, and operator of enhanced geothermal systems that applies horizontal drilling and hydraulic fracturing techniques from the oil and gas industry to produce baseload geothermal power.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures